NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Citius Pharmaceuticals, Inc. Common Stock (CTXR) Stock Analysis

Citius Pharmaceuticals, Inc. Common Stock (CTXR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CTXR

$0.59

−$0.01 (−2.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTXR with… →

CTXR Key Statistics

As of Sep 4, 2026
Trading
Open
$0.60
Previous Close
$0.60
Day's Range
0.58–0.61
52-Week Range
0.47–2.19
Volume
299.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.00
Valuation
Market Cap
$16.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.27
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.71
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$37.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.45M
1-Year Return
−48.87%
Dividend and dates
Avg Volume
558.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTXR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.32%
2025−80.58%
2024−78.86%
2023−4.18%
2022−48.70%
2021+50.98%
2020+0.00%
2019−1.92%
2018−72.63%
2017−42.94%
2016 (partial year)−40.80%

As of September 4, 2026.

CTXR Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$37.43M—
2024$0.00−$39.14M—
2023$0.00−$32.54M—
2022$0.00−$33.64M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$38.53M−$37.43M—
2024$0.00—−$42.00M−$39.14M—
2023$0.00—−$36.73M−$32.54M—
2022$0.00—−$33.32M−$33.64M—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

CTXR Valuation vs Biotechnology Median

Median of 656 stocks
MetricCTXRBiotechnology medianvs median
P/S ratio2.2715.260.1x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Citius Pharmaceuticals, Inc. Common Stock (CTXR) carries a market capitalisation of $16.13M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 23 employees.

The most recent close on file for CTXR is $0.59, dated September 4, 2026. That is −$0.01 (−2.33%) against the previous close. Over the past 52 weeks the price has ranged from $0.47 to $2.19. The latest close sits 25.37% above that 52-week low.

Financial Health

In fiscal 2025, Citius Pharmaceuticals, Inc. Common Stock reported revenue of $0.00. The same year closed with a net loss of $37.43M. Profit margin runs at 0%. Trailing earnings per share are −1.71.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.27. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −48.87%. Measured over 10 years, that is −45.18% a year compounded. The reported beta is 1. Annualized volatility over the trailing 10 years is 104.45%.

Growth & Income

The record shows no dividend for CTXR.

So far in 2026 the price is −24.32%. The strongest complete calendar year on file is 2021 at +50.98%; the weakest is 2025 at −80.58%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Citius Pharmaceuticals, Inc. Common Stock (CTXR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Citius Pharmaceuticals, Inc. Common Stock CTXR $16.13M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Citius Pharmaceuticals, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Citius Pharmaceuticals, Inc. Common Stock

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Visit website →